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Highlights 
 
 A J-shaped dose-response was observed following N-methyl-N-nitrosourea 
treatment 
 Mechanistic studies indicated a possible role of p53 
 Hormesis is rare in Swansea University genotoxicity datasets generated since 
2004 
 Hormesis is, therefore, likely to be infrequent for genotoxic agents 
 
 
 
Abstract 
Hormesis is defined as a biphasic dose-response where biological effects of low doses of 
a stressor demonstrate the opposite effect to high-dose effects of the same stressor. 
Hormetic, or J-shaped, dose-response relationships are relatively rarely observed in 
toxicology, resulting in a limited understanding and even some skepticism of the concept. 
Low dose-response studies for genotoxicity endpoints have been performed at Swansea 
University for over a decade. However, no statistically significant decreases below 
control genotoxicity levels have been detected until recently. A hormetic-style dose-
response following a 24h exposure to the alkylating agent N-methyl-N-nitrosourea 
(MNU) was observed in a previous study for HPRT mutagenesis in the human 
lymphoblastoid cell line AHH-1. A second recent study demonstrated a J-shaped dose-
response for the induction of micronuclei by MNU in a 24h treatment in a similar test 
system. Following mechanistic investigations, it was hypothesized that p53 may be 
responsible for the observed hormetic phenomenon. As genotoxic carcinogens are a major 
causative factor of many cancers, consideration of hormesis in carcinogenesis could be 
important in safety assessment. The data examined here offer possible insights into 
hormesis, including its estimated prevalence, underlying mechanisms and lack of 
generalizability.   
 
Keywords: Hormesis, adaptive response, genotoxicology, alkylating agents, low-dose, 
carcinogens 
 
1.  Introduction 
1.1 Hormesis and genetic toxicology 
 
In biological systems, it is sometimes observed that the frequency of adverse events 
decreases below the background frequency at low doses before it starts to increase [1, 2]. 
As the dose-response contains both sub-background damage and toxic phases, it conforms 
to a “biphasic” trend, producing a J- or U-shaped, or inverted J- or U-shaped, dose-
response curve [3][4]. This form of dose-response is frequently referred to as the 
biological phenomenon “hormesis” if this follows a single exposure to a toxin, toxicant or 
radiation (Figure 1). If at least one exposure to an agent induces a protective effect 
against a subsequent larger exposure, this would be described as an “adaptive response”. 
Although hormesis and adaptive responses demonstrate some overlap, it is important to 
recognize these as distinct phenomena. Such responses of a cell or organism to a low dose 
of toxic agent is considered to be an adaptive compensatory process following an initial 
disruption in homeostasis [4]. 
 
Hormesis and adaptive responses are concepts shrouded in controversy and confusion[5]. 
There is an ongoing debate on the probability of hormesis existing. Some proponents 
claim that hormesis has been ignored by the scientific community, due to bias towards a 
linear no threshold (LNT) dose-response model [6], which has been favoured in 
genotoxicology, or to a threshold model in other areas of toxicology. As well as debates 
over whether hormesis and adaptive responses exist, there is the issue of whether these 
are generalisable phenomena, partly owing to their relative infrequency in 
genotoxicological datasets. To be generalisable, such phenomena should occur at 
frequencies approaching universality, being observed with all or most organisms, agents, 
endpoints and genotypes [7]. Therefore, a key aspect of determining whether hormesis is 
generalisable in genetic toxicology is whether it occurs in all or in the vast majority of 
dose-responses, or whether its occurrence is more limited [7]. However, based on current 
dose-responses, hormetic-style responses are in fact in the minority [8][9-11] and it also 
appears that no universal mechanism exists for hormesis, perhaps preventing it from 
being adopted in toxicological risk assessment [12]. However, the mechanisms underlying 
hormesis have previously been hypothesized and speculated upon [13]. The fact that 
previous studies were not aimed at the low-dose region means that it is unsurprising that 
hormetic effects were rarely observed. Whether current study designs are not optimized to 
capture a transient hormetic effect, whether few studies use low doses, or whether 
hormesis is truly not generalisable is unclear. 
 
1.2 Genotoxicity dose-response data generated at Swansea University 
J-shaped dose-responses have been observed relatively recently in our laboratory at 
Swansea University. Thomas et al. reported the first of these in 2013 for HPRT mutant 
frequency in the human lymphoblastoid cell line AHH-1 (Table 1). In their study, a 
statistically significant decrease in mutant frequency below the vehicle control level was 
observed for two low concentrations of MNU, 0.005 and 0.0075 µg/ml. The magnitude of 
the reduction relative to vehicle control was 45%. The second of these J-shaped dose-
responses will be discussed in Results. Prior to these findings, no such J-shaped dose-
responses had been identified. For over a decade, the effects of low concentrations of 
chemical agents on in vitro cell-based test systems have been studied within our 
laboratory (Table 1), which has extensive datasets from genetic toxicology testing 
conducted with a high standard of quality control. The use of low concentrations 
minimizes possible artefactual reductions in genotoxicity due to confounding cytotoxicity, 
and these conditions are therefore likely to facilitate the observation of hormesis should it 
occur. Both linear and non-linear (threshold) dose-responses have been observed thus far 
at Swansea University, yet only one previously published study to date has produced a J-
shaped dose-response [14]. The data contain a large number of experiments performed 
using the same facilities, equipment and laboratory protocols, facilitating direct 
comparisons between different chemical dose-responses. Furthermore, similar chemicals, 
exposure times, assays and cell types were often used across the different studies. For 
example, the majority of studies used MCL-5, AHH-1 or TK6, which are all human 
lymphoblastoid cell lines, with MCL-5 even being derived from AHH-1. The collection 
of datasets therefore offers novel insights into the prevalence of hormesis in genetic 
toxicology and the conditions required for its occurrence. This paper explores hormesis 
further by presenting new data for another J-shaped dose-response and considering this 
finding in relation to previous datasets for the low-dose region. The study could also 
provide further information on whether hormesis is likely to be a generalizable 
phenomenon. 
 
 
2. Materials and methods 
 
2.1 Test chemical. N-methyl-N-nitrosourea (MNU) (CAS Number: 684-93-5; molecular 
weight: 103.08; purity: 66%) was purchased from Sigma-Aldrich (Dorset, UK) and stored 
according to the manufacturer’s instructions (4oC, sealed). The relatively low purity of 
66% was associated with the inherent instability of MNU, which required the “impurities” 
acetic acid (2.3%) and H2O for its stabilisation. The presence of these compounds was not 
deemed to have any effects on genotoxicity or hormesis, due to their extremely low 
concentrations following subsequent dilutions of the test chemical stock. MNU, of which 
1g (not including impurities) was provided by the manufacturer, was diluted in DMSO 
(Fisher Scientific), as per the methods followed in a previous study using MNU {Thomas, 
2013 #15}. Dilutions from a master stock were made immediately before use and stored 
in the dark at 4oC for approximately 5 min until use. It was ensured that the solid was 
fully dissolved prior to further dilution of the stock solution, to prevent underestimation of 
toxic effects. When handling MNU, safety precautions, including arm length gloves and 
protective clothing, were implemented at all times.  
2.2 Cell culture. The human lymphoblastoid cell lines TK6 and NH32 were cultured in 
RPMI 1640 medium (Life Technologies) supplemented with 1% L-glutamine (Life 
Technologies) and 10% donor horse serum (BDGentest, Oxford). The cells were 
maintained in culture at densities between 1x105 and 1x106 cells/ml. TK6 cells were 
obtained from the Health Protection Agency Culture Collections, UK. NH32 cells were a 
kind gift from Professor Gerald Wogan, Massachusetts Institute of Technology, USA. 
2.3 In Vitro Micronucleus Assay. Please refer to Chapman et al.31 (2015) for the method 
followed.   
2.4 RNA isolation and quantitative real time-PCR. Real-time PCR was used to 
investigate relative mRNA expression levels for methylpurine-DNA glycosylase (MPG) 
in response to 24h exposure to MNU in TK6 cells. Changes might indicate whether MPG, 
a DNA repair glycosylase targeting methylation at N7-guanine sites, could have a notable 
impact on the observed dose-response. RNA was extracted from treated cell samples 
using RNeasy Mini Kit (Qiagen) and RNase-free DNase I Set (Qiagen) using the 
recommended protocols and for various treatment time points and concentrations. 
Synthesis of cDNA from RNA was completed using Quantitect Reverse Transcription Kit 
(Qiagen). qRT-PCR was performed using these samples, using Quantifast SYBR Green I  
(Qiagen) and appropriately designed and optimised primers. Primer nucleotide 
sequences: MPG forward: 5’ GGTCCGAGTCCCACGAAGCC 3’; MPG reverse: 5’ 
CTGCATGACCTGGGCCCCG 3’; ß-actin forward: 5’ GATGGCCACGGCTGCTTC 3’; 
ß-actin (ACTB) reverse: 5’ TGCCTCAGGGCAGCGGAA 3’. A BioRad iCycler was used 
to perform the real-time PCR and analysis using a standard curve was completed using 
BioRad iQ5 software. 
 
2.5 Protein isolation and immunoblotting. To investigate MPG protein levels in TK6 
cells, protein isolation and subsequent immunoblotting was used. This was to observe 
whether MPG expression was altered at the protein level without being altered at the 
transcription (in this case, mRNA) level. TK6 cell suspensions treated for 24h with MNU 
within the hormetic dose range were centrifuged at 250xg for 7min and washed twice in 
4oC phosphate-buffered saline (PBS) (Gibco). Cells were lysed at 4oC using 1x 
radioimmuno-precipitation lysis buffer (RIPA) (Sigma-Aldrich) supplemented with 
protease inhibitor cocktail (Sigma-Aldrich) and kept on ice for 5 min prior to vortexing, 
followed by centrifugation at 9,300 xg for 10 min at 4°C. Protein concentration was 
determined using the DC quantification assay (Biorad). Proteins (40µg) were mixed at a 
1:1 ratio with 1x Laemmli buffer (Sigma-Aldrich) and resolved on a 12% SDS 
polyacrylamide gel. Proteins were then electroblotted onto Immun-Blot PVDF 
membranes (Biorad) and blocked for 1h with 1x Tris-buffered saline-Tween 20 
containing bovine serum albumin (BSA) (5% solution) (Sigma-Aldrich). Membranes 
were separated and probed at 4°C overnight with MPG antibody (1:1000 dilution; M6195; 
Sigma-Aldrich) diluted in 5% BSA. After four washes with 1x Tris-buffered saline-
Tween 20 containing 5% BSA, the membrane was incubated for 1h in rabbit anti-mouse 
secondary antibody (1:10,000 dilution; ab6728-1, Abcam). Following this, a further three 
washes with 1x TBS-Tween 20 containing 5% BSA were performed. To correct for 
protein loading differences, blots were probed with mouse antibody to ß-actin (ab8226-
100, abcam), followed by rabbit anti-mouse secondary antibody. Immun-Star WesternC 
Chemiluminescence Kit (Biorad) was used for the immunodetection of proteins. Band 
densitometry was determined using the Quantity One software (Biorad). 
 
2.6 O6-benzylguanine as an inhibitor of O6-methylguanine DNA-methyltransferase 
(MGMT). To investigate whether the DNA repair enzyme MGMT is responsible for the 
hormetic dose-response, O6-benzylguanine (O6BG) (Sigma-Aldrich) was used as a 
MGMT inhibitor. O6BG in powder form was dissolved in methanol, and cells were 
treated with 10µM O6BG for 1h prior to dosing. Appropriate controls were included, i.e., 
methanol control, DMSO control, untreated control and O6BG only control. 
 
 2.7 Statistical analysis. At least three biological replicates were completed for all 
experiments (except where indicated): replicates were performed on separate days with 
separate vials of cells and test chemicals. “n” refers to the number of these individual 
biological replicates. The mean values of these replicates are presented on the graphs, 
with error bars referring to standard deviation between replicates. Data were log-
transformed and assessed using the Levene statistic as to whether these conformed to a 
normal distribution. A one-way ANOVA with Dunnett’s 2-sided post hoc analysis was 
then performed to identify the first statistically significant increase or decrease relative to 
background MN levels (i.e., lowest observed effect level (LOEL)). The Dunnett’s test was 
selected because it permits multiple comparisons between treatments. Using the 2-sided 
Dunnett’s test is appropriate for the detection of both increases in frequency for 
genotoxicity relative to the vehicle control, and possible hormesis at low doses. 
 
3. Results   
3.1 MNU induced a J-shaped dose-response for two genotoxicity endpoints 
 
J-shaped dose-responses are relatively infrequent in genetic toxicology, and it was 
noteworthy, therefore, that our laboratory has identified two hormetic dose-response 
curves on separate occasions for two different endpoints following a 24h treatment in 
human lymphoblastoid cell lines with the same chemical: N-methyl-N-nitrosourea 
(MNU).  
 
The second J-shaped dose-response observed for MNU is presented here for the first time 
(Figure 2A), with the raw data in tabular form (Appendix A). The full dose-response for 
the higher dose region is included in a previous publication, with a LOEL at 0.46 µg/ml 
and a clear dose-dependent mutagenic effect at higher doses [31]. The full dose-response 
up to 1.1 µg/ml is also included here in a different form (Appendix B) for the purpose of 
illustrating that the hormetic dose belongs to a broader “J-shaped” dose-response. Rather 
than a frequency of gene mutations (HPRT), as in the study of Thomas et al.14, this study 
measured the frequency of micronuclei, indicative of a clastogenic effect in 
mononucleated cells. The statistically significant decrease in DNA damage occurred at 
(0.009 µg/ml), similar to the study by Thomas et al. (2013). The magnitude of the 
reduction in micronucleus frequency relative to the vehicle control was 55%. 
 
Further investigations were conducted to determine the mechanistic basis of the reduction 
below control levels for micronucleus frequency (Figure 2A). The induction of 
micronuclei in the p53-deficient cell line, NH32, was assessed at the same dose range as 
in TK6 to investigate whether functional p53 might be involved in the J-shaped dose-
response. Unlike TK6, NH32 cells produced no significant decrease below control 
damage levels and therefore no “hormetic” dose-response (Figure 2A). NH32 cells have 
an approximately 1.8x greater background micronucleus frequency than TK6, these being 
1.23% and 0.67%, respectively in Figure 2A.  
 
Two DNA repair proteins were studied to determine their involvement in the J-shaped 
dose-response. N-methylpurine DNA glycosylase (MPG) is involved in identifying 
alkylated bases, such as N7-methylguanine[34], and subsequent initiation of the base 
excision repair (BER) pathway due to abasic site formation[35]. MPG has previously 
been identified as being responsible for the threshold dose-response induced by alkylating 
agent ethyl methanesulfonate [24]. qRT-PCR and Western blotting were employed to 
investigate relative MPG mRNA and protein abundance, respectively, to study gene 
expression. MPG mRNA concentrations did not produce a statistically significant change; 
however, there was an increase of 1.5-fold observed at 0.009 µg/ml, prior to a 0.5-fold 
reduction below control levels at 0.114 µg/ml (Figure 2D). Similarly, MPG protein 
abundance (Figure 2C) remained unchanged across the dose range, including the 0.009 
µg/ml treatment.  
 
As Thomas et al. identified the involvement of MGMT in the J-shaped dose-response, the 
MGMT-inhibitor O6-benzylguanine (O6BG) was used in TK6 cells to determine whether 
DNA repair via MGMT might contribute to the hormetic curve presented in Figure 2A. 
MGMT performs direct repair of O6-methylguanine DNA adducts [36], which are 
typically induced by alkylating agents that target oxygen sites. No statistically significant 
difference was observed between cells with normal and inhibited MGMT (Figure 2D). 
Interestingly, while a decrease relative to control was observed at 0.009 µg/ml in cells not 
treated with the inhibitor, this was not statistically significant, in contrast to the dose-
response in Figure 2A.  
 
 
4. Discussion 
The aim of this study was to further explore the biphasic dose-responses observed in 
genotoxicity studies within our laboratory, including the underlying mechanistic basis of 
such phenomena. The primary data presented here focused on a single chemical, MNU, 
which was found to induce two separate biphasic dose-responses for two different 
genotoxicity endpoints.  
 
4.1 J-shaped dose-responses are observed infrequently in our laboratory 
 
Following this study, a total of two J-shaped dose-responses were identified among the 
137 datasets considered here. In over a decade of the low-dose region being specifically 
studied in this laboratory, the fact that these were the first dose-responses to exhibit 
hormesis was intriguing, especially since they occurred for the same genotoxic agent for 
two different endpoints in studies of comparable design. In many cases, hormesis may be 
missed due to a lack of focus on the low-dose region and a lack of statistical power of the 
studies undertaken; this was not the case with our studies. It was noted that only one 
concentration (Figure 2A, B) of 0.009 µg/ml produced a significant decrease 
corresponding with hormesis. However, due to the high level of statistical significance (p 
< 0.01) and reproducibility of this result, we can be confident that this is a true biological 
effect. These reasons also imply that the performance of three replicates is sufficient. 
Indeed, it is possible that other doses within the region of 0.009 µg/ml may have been 
hormetic; for example, a small decrease was observed at 0.011 µg/ml (Appendix A). 
However, as this was not statistically significant, this dose cannot be concluded to be 
hormetic. 
 
The HPRT assay study of Thomas et al.14 produced the statistically significant reduction 
in mutation levels below vehicle control at concentrations in the region of 0.009 µg/ml, as 
was observed in the present study (Figure 2). The fact that similar hormetic dose ranges 
were identified makes a case for hormesis more convincing in both instances. However, 
previous studies that used a similar dose range of MNU did not produce a J-shaped dose-
response. A study by Doak et al. in 2007 included a linear dose-response for MNU in 
AHH-1 cells for micronucleus induction in binucleated cells and HPRT mutant frequency 
[17]. In contrast to the data presented in Figure 2, Doak et al. used a different cell line, 
AHH-1, and also the cytokinesis-blocked version of the assay involving cytochalasin B as 
a cytokinesis inhibitor. Prior to Thomas et al.14, Doak et al. 17 also performed the HPRT 
experiment with MNU using the same protocol and a similar dose-range, yet 0.0075 
µg/ml was found to be the LOEL, rather than a “hormetic” dose as Thomas et al. 
observed. It is unclear why the two studies produced different outcomes when the same 
concentrations, endpoints and cell lines were used. It is possible that minor technical 
differences could be responsible. For example, the Doak17 and Thomas14 studies were 
performed several years apart and undoubtedly used different batches or ages of test 
chemical. 
 
Only the acute, 24h dosing revealed hormetic effects for MNU, whereas the chronic 
dosing for both MNU and MMS did not give evidence for hormesis [31]. Originally, it 
was hypothesized that if hormesis were to be identified it would more likely be observed 
following the chronic dosing. It is possible that this relates to a narrow dose window and 
specific temporal conditions being required for observation of a hormetic effect.   
 
Due to the abundance of published data that centered on the low-dose region (Table 1), 
this study presents an opportunity to estimate the prevalence of J-shaped (i.e., biphasic) 
dose-responses for experiments performed in the same laboratory using similar protocols. 
Based on this literature, J-shaped dose-response curves were found to occur infrequently 
(2 cases in 137 dose-responses, a 1.4% frequency). This very low frequency of biphasic 
dose-responses suggests that hormesis itself is not a generalisable phenomenon, as it does 
not occur for all endpoints, cell types and chemicals tested in systems that have been 
shown to identify J-shaped curves. Chemical specificity also appears to be an important 
factor, as only MNU thus far has exhibited a hormetic-like effect. Hormesis could be 
assay-, endpoint- or cell-specific, and different conditions may be required for hormesis in 
the different cases. If so, this also argues that it is not broadly generalisable.  
 
While there are similarities between hormesis occurring after exposure to an array of 
individual doses and adaptive responses occurring after sequential treatments, the two 
should not be conflated. Appendix C presents data relating to the possibility of an 
adaptive response resulting from a pre-treatment with genotoxic agent prior to a 
subsequent larger concentration. To extend the present study, the “hormetic” dose of 
MNU, 0.009µg/ml, was employed as a priming dose. A reduction in the genotoxic effect 
of a high dose of MNU was not observed (Appendix C) and therefore provided no 
evidence of an adaptive response when a dose that had been shown to induce hormesis 
(Figure 2) was used as a priming dose prior to a larger “challenge” dose.
Statistical power is a factor in the ability to detect hormesis and adaptive responses. Statistical 
power will increase with a greater magnitude of biological effects. In priming dose 
experiments, therefore, the reduction from the more potent treatment level is relatively easily 
measured. However, a chronic study is likely to involve comparisons between smaller 
exposures, meaning a reduction effect is more difficult to detect within a dataset of the same 
size.  That hormesis and adaptive responses should be regarded as distinct processes, rather 
than manifestations of a single process, is also reflected in studies in yeast, where a dose of 
hydrogen peroxide that induces a clear adaptive response to a subsequent high-dose challenge 
does not induce hormesis in the original sense of a biphasic curve from single exposures to 
each dose37. Thus, one may see hormetic treatments that do not induce an adaptive response, 
and one may see an adaptive response with no concomitant hormesis. 
 
The potential merit in identifying the hormetic dose range relative to the toxic dose range 
extends to the possible use of hormesis in risk assessment. However, this would require full 
dose-responses with multiple doses both in the “hormetic” and “toxic” regions.  Given the 
lack of generalisability of hormesis, as was reflected in the datasets analysed in this study 
(Table 1) and other sources 7,9,38,60, hormesis-based risk-assessment remains an unrealistic 
aim. 
 
 
4.2 p53 status may contribute to the J-shaped dose-response 
 
The mechanisms underlying the J-shaped dose-response observed in Figure 2 were 
investigated using several different experimental approaches. The first of these involved a 
comparison of p53-null NH32 cells to isogenic, p53-competent TK6 cells. The results 
suggested that functional p53 might be responsible for the J-shaped dose-response for 
micronucleus frequency observed in the latter cell line. Previous publications have also 
identified the involvement of p53 in genotoxicity dose-responses for TK6 cells [28, 31]. It is 
unclear whether p53 was responsible for Thomas et al.’s dose-response; unlike TK6 cells, 
AHH-1 cells are heterozygous for p53 function due to a base pair substitution at codon 282, 
with consequences including loss of the G1 checkpoint and delayed apoptotic cell death[37]. 
Indeed, more efficient repair of apurinic/apyrimidic sites by MPG in wild-type p53 cells than 
mutant p53 cells[38] may explain why a different mechanism may be responsible for Thomas 
et al.’s J-shaped dose-response. In relation to this, MPG protein expression (Figure 2C) 
remained unchanged at the present study’s hormetic dose, although a minor, non-significant 
increase in mRNA, which corresponded with the hormetic dose, was observed (Figure 2B). 
The fact that MPG expression was essentially unchanged does not rule out a role in the 
hormetic dose-response, as MPG is known to be a selective regulator of p53[38]. In 
unstressed cells, MPG binds to p53 and represses its activity [38]. Perhaps the 0.009 µg/ml 
concentration of MNU was sufficient to dissociate p53 and MPG without being sufficient to 
up-regulate MPG expression.  
 
In a similar mechanistic analysis, MGMT activity was not observed to change in the hormetic 
dose range, suggesting that it was not responsible for the TK6 J-shaped dose-response curve 
in Figure 2A. Heterogeneity in efficiency of inhibition by O6BG across a cell population has 
been suggested as a source of high statistical variability in MGMT- samples[14], and this may 
mask any effect of MGMT.  This may also be due to the cell line, TK6, expressing MGMT at 
non-detectable levels[39]. As there is limited evidence linking MGMT and p53 in human cells 
[19], this perhaps indicates that MGMT operates independently of p53, as Thomas et al. 
found that MGMT appeared to be responsible for the J-shaped dose-response in AHH-1 cells. 
DNA repair mechanisms have been implicated in genotoxin-induced hormesis in a variety of 
systems [14, 40-43]. Indeed, MGMT has been hypothesized to be responsible for hormetic 
dose-responses following exposure to alkylating agents [44, 45]. As MGMT is an inducible 
enzyme and repairs the highly mutagenic O6-methylguanine lesion, induction of MGMT 
would readily explain the reduction in mutant frequency observed by Thomas et al. It is 
acknowledged that there may be additional underlying mechanisms for hormesis, which 
include but are not limited to alterations in apoptosis [46, 47], [48], [49], [50] cell proliferation [42, 
51, 52] and antioxidant capacity [53],[54, 55],[56],[57],[25].  
 
 
4.3 Conclusions 
 
The mechanisms responsible for J-shaped curves for low-dose regions and genotoxicity 
endpoints were further explored. New MNU data were presented, with p53 predicted to partly 
explain the dose-response. J-shaped curves were found to occur at very low frequency in the 
literature generated at Swansea University, suggesting that hormesis is unlikely to be 
generalisable across different endpoints, cell types and test chemicals.  This fact argues that 
hormesis cannot serve as a default assumption in risk assessment. While hormesis-based risk 
assessment is not feasible, an awareness of hormesis contributes to the broad-based 
understanding of dose-response relationships.  
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Appendix A. Raw data for the micronucleus dose-response presented in Figure 2A. Only 
0.009 µg/ml produced a statistically significant decrease compared to the DMSO-treated 
vehicle control, denoted by ** (i.e., p=0.003). 
 
MNU (µg/ml) Data points for individual replicates 
0 0.679 0.861 0.485 
0.593 0.670 0.683 
0.928 1.025 0.977 
0.620 0.572 0.364 
0.002 0.544 0.590 0.492 
0.005 0.772 0.660 0.585 
0.475 0.502 0.244 
0.009 ** 0.357 0.310 0.220 
0.011 0.455 0.389 - 
0.018 0.878 0.658 0.390 
0.023 0.744 0.750 0.561 
0.034 0.609 0.455 0.562 
0.045 1.206 0.319 0.440 
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Legends for figures 
 
Figure 1. Schematic diagram of a J-shaped (biphasic) dose-response curve characteristic of 
hormesis. The hormetic region represents protective overcompensation by cellular processes 
to reverse damage, resulting in a proportion of endogenous damage also being repaired and 
leading to reduction of damage below background damage levels. This leads to an apparent 
improvement in cellular fitness. At doses lower than those within the hormetic zone, levels of 
agent are too low to stimulate a measurable effect. At high doses, toxic effects are observed. 
Adapted from: [58] and [59] 
 
Figure 2A. MNU 24h treatment dose-response for the micronucleus assay in TK6 cells (n= or 
>2), centering on the low-dose, “hormetic” region. Data points for individual replicates are 
represented by circular symbols. A statistically significant decrease relative to the 0µg/ml 
control was observed at 0.009µg/ml (p<0.01, denoted by **). B. Average values for MNU 
24h treatment dose-response for the micronucleus assay in TK6 cells (n=3, black line) and 
NH32 cells (n=2, grey line). No statistically significant decrease was observed in NH32 
(p>0.05). C. Western blotting for DNA repair glycosylase, MPG, demonstrated no dose-
dependent changes across MNU doses tested (n=3). One representative replicate is shown in 
C. D. No statistically significant changes in MPG mRNA expression levels (n=3, line) were 
observed. DNA repair enzyme MGMT’s (n=4, bars) effects upon micronucleus frequency 
(%), studied via use of a MGMT inhibitor (O6BG), also remained unchanged (p>0.05) at the 
hormetic dose range. 
 
 
Appendix B. Illustration of the approximately “J-shaped” nature of the dose-response curve. 
A full dose-response for MNU MN frequency (%), including significantly genotoxic doses 
not included in Figure 2A and 2B, as well the hormetic dose (p < 0.05 denoted by *, p < 0.01 
denoted by **, p < 0.001 denoted by ***). The log10 of the values for MNU dose (x axis) was 
plotted in order to account for the differences in magnitude across the tested dose-range. 
 
Appendix C. Micronucleus frequency (%) following a priming dose study (n=2). TK6 cells 
were pre-treated with the dose of MNU observed previously to induce a statistically 
significant decrease in micronucleus frequency (0.009 µg/ml, Figure 2A), for 24h. A dose of 
0.2 µg/ml was then administered to cells and cells were incubated for 24h. No statistically 
significant difference was observed between cells treated with the priming dose and those 
with no priming dose. 
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Table 1. Summary of the dose-responses from positive genotoxicity assays for diverse 
endpoints generated at Swansea University. Only one of 136 published datasets produced a J-
shaped dose-response (in bold). The current study increases the number to two of 137 
datasets.  Criteria for inclusion included a dose-response (i.e., > or = 3 treatment 
concentrations) for a genotoxicity endpoint. CBMN = Cytokinesis-blocked micronucleus 
assay. EMS = ethyl methanesulfonate. ENU = N-ethyl-N-nitrosourea. HPRT = Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) Gene Mutation Assay. MMS = methyl 
methanesulfonate. MN = Micronucleus Assay. MNU = N-methyl-N-nitrosourea. RSMN = 
Reconstructed Skin Micronucleus Assay.  
 
 
Publication Chemical Number 
of dose-
responses 
Genotoxicity 
Assay/Endpoint 
Exposure 
time 
Cell 
line/type 
Parry et al., 2004 
[15] 
8-
Hydroxyquinoline, 
MMS, 4-
nitroquinoline 1-
oxide 
3 CBMN 1 CC AHH-1 
Jenkins et al., 
2006 [16] 
Deoxycholic acid 
(pH 5.5 or 7.4) 
2 CBMN 24 h OE33 
Doak et al., 2007 
[17] 
MMS, MNU, 
EMS, ENU 
12 CBMN, HPRT 24 h AHH-1, 
MT-1 
Jenkins et al., 
2008 [18] 
Deoxycholic acid 1 CBMN 21 h OE33 
Doak et al., 2008 
[19] 
MMS  2 HPRT, N7-meG 
adducts 
24 h AHH-1 
Johnson and 
Parry, 2008[20] 
Bisphenol A, 
rotenone 
2 CBMN 24 h AHH-1, 
MCL-5, 
V79 
Johnson et al., 
2010a [21] 
Vinblastine, 
diethylstilboestrol 
8 CBMN, MN (no 
cytochalasin B) 
3h, 24h CHO 
Johnson et al., 
2010b [22] 
Sudan-1, Para Red 7 CBMN, HPRT 24 h AHH-1, 
MCL-5 
Kayani and Parry, 
2010 [23] 
Ethanol, 
acetaldehyde 
2 CBMN 22 h MCL-5 
Zair et al., 2011 
[24] 
EMS, ENU 12 CBMN, HPRT 24 h AHH-1 
Seager et al., 
2012 [25] 
H2O2, KBrO3, 
menadione 
6 CBMN, HPRT 4 h AHH-1 
Singh et al., 2012 
[26]  
Fe2O3, Fe3O4 
(dextran-coated 
and uncoated 
ultrafine 
superparamagnetic 
iron oxide 
nanoparticles) 
4 CBMN 24 h MCL-5 
Thomas et al., 
2013 [14] 
MNU 1 HPRT 24 h AHH-1 
Manshian et al., 
2013 [27] 
Single walled 
carbon nanotubes 
11 CBMN, HPRT 24 h, 48 h BEAS-2B, 
MCL-5 
Brüsehafer et al., 
2014 [28] 
Mitomycin-C 
(4h), cytarabine 
(24h) 
4 CBMN 4 h, 24 h TK6/NH32 
Chapman et al., 
2014 [29] 
MMS, 
Mitomycin-C, 
H2O2, Methyl 
carbamate 
5 RSMN (CBMN) 
in EpiDerm 
48 h Primary 
epidermis 
Brüsehafer et al., 
2015 [30]  
4-Nitroquinoline 
1-oxide 
11 CBMN, MN (no 
cytochalasin B), 
HPRT, Comet 
assay 
4 h MCL-5, 
AHH-1 
L5178Y 
Chapman et al., 
2015 [31] 
MMS, MNU  6 MN (no 
cytochalasin B) 
24h, 5 day, 10 
day 
TK6, NH32 
Manshian et al., 
2015 [32] 
CdSe/ZnS 
nanoparticles 
24 CBMN 1 and 3 cell 
cycles 
HFF-1, 
BEAS-2B, 
TK6 
Shah et al., 2016 
[33] 
Benzo[a]pyrene 11 CBMN, HPRT 4h, 23h TK6 
Total = 
136 
 
 
 
 
 
